– ARA290 (Cibinetide)
$75.00 – $100.00Price range: $75.00 through $100.00
Product Classification
Classified as an EPO-derived tissue protective peptide
Description
ARA290 (Cibinetide) is a small peptide derived from erythropoietin (EPO) designed to selectively engage the innate repair receptor (IRR) without erythropoietic effects.
Research explores neuroprotection, nociceptive modulation, inflammatory signaling, and vasculopathy models.
Specifications
- Molecular Type: EPO-derived non-erythropoietic peptide
- Mechanism : Mechanism IRR activation and tissue protective signaling
Research Notes
- Neuropathic Pain: studies in diabetic neuropathy models report nociceptive modulation.
- Microvascular: interest in microcirculatory dysfunction and endothelial protection.
- Immunomodulation: anti-inflammatory cytokine balance and tissue repair pathways observed in
preclinical work. - Erythropoiesis-Sparing: avoids hematologic responses typical of EPO derivatives.
Regulatory StatementFor research use only. Not for human or animal consumption.
Not evaluated by FDA. Not intended to diagnose, treat, cure, or prevent disease.
Reviews
There are no reviews yet.